Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $17.11.
Several research analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Friday, August 30th. Barclays upped their target price on Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 19th. Lake Street Capital dropped their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Thursday, October 31st.
View Our Latest Stock Report on Alphatec
Alphatec Stock Up 0.4 %
Hedge Funds Weigh In On Alphatec
A number of large investors have recently made changes to their positions in ATEC. XTX Topco Ltd purchased a new position in Alphatec during the third quarter valued at approximately $69,000. Net Worth Advisory Group purchased a new position in shares of Alphatec during the 3rd quarter valued at $76,000. Comerica Bank increased its stake in shares of Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after acquiring an additional 2,534 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after acquiring an additional 6,998 shares in the last quarter. Finally, Tempus Wealth Planning LLC acquired a new stake in Alphatec during the third quarter valued at $107,000. Institutional investors and hedge funds own 66.35% of the company’s stock.
About Alphatec
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
See Also
- Five stocks we like better than Alphatec
- What is the Dogs of the Dow Strategy? Overview and Examples
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- Consumer Staples Stocks, Explained
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- Airline Stocks – Top Airline Stocks to Buy Now
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.